3-Indoleacetonitrile CAS 771-51-7 Purity > 99.0% (HPLC) Hoobkas High Quality Featured duab

3-Indoleacetonitrile CAS 771-51-7 Purity > 99.0% (HPLC) Lub Hoobkas Zoo

Lus piav qhia luv luv:

Lub npe tshuaj: 3-Indoleacetonitrile

CAS: 771-51-7 Nr

Purity:> 99.0% (HPLC)

Cov tsos mob: Lub teeb daj rau lub teeb xim av hmoov

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Xa email rau peb

Product Detail

Yam khoom

Khoom cim npe

Nqe lus piav qhia:

Shanghai Ruifu Chemical Co., Ltd. yog cov chaw tsim khoom thiab cov chaw muag khoom ntawm 3-Indoleacetonitrile (CAS: 771-51-7) nrog cov khoom zoo, kev lag luam ntau lawm.Txais tos kom xaj.

Chemical Properties:

Tshuaj npe	3-Indoleacetonitrile cov tshuaj
Synonyms	Indole-3-Acetonitrile;2-(1H-Indol-3-yl) acetonitrile
CAS Nr	771-51-7
CAT Number	Qauv: RF-PI1602
Tshuag xwm txheej	Nyob rau hauv Tshuag, ntau lawm Scale mus txog Tons
Molecular Formula	C10H8N2
Molecular Luj	156.19 Nws
Melting Point	33.0 ~ 36.0 ℃ (lit.)
Qhov ntom	1, 1566
Solubility	Soluble nyob rau hauv Methanol (yuav luag Transparency)
Hom	Ruifu Tshuaj

Specifications:

Yam khoom	Specifications
Qhov tshwm sim	Lub teeb daj rau lub teeb xim av hmoov
Purity / Analysis Method	> 99.0% (HPLC)
Poob rau ziab	<1.00%
Ib leeg Impurity	<0.50%
Tag nrho cov impurities	<1.00%
1 H NMR Spectrum	Raws li tus qauv
Test Standard	Enterprise Standard
Kev siv	Pharmaceutical Intermediates

Pob & Cia:

Pob: Lub raj mis, Aluminium ntawv ci hnab, 25kg / Cardboard Nruas, los yog raws li tus neeg yuav tsum tau muaj.

Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb thiab noo noo.

Qhov zoo:

FAQ:

Daim ntawv thov:

3-Indoleacetonitrile (CAS: 771-51-7),Reactant rau kev npaj ntawm: Tryptophan dioxygenase inhibitors pyridyl-ethenyl-indoles raws li muaj peev xwm anticancer immunomodulators;Histone deacetylase inhibitors;Muaj peev xwm kinase inhibitors;Kv7/KCNQ potassium channel activators;Kinesin-Specific MKLP-2 Inhibitor;Tshuaj tua kab;Muaj peev xwm PET cov kab mob qog noj ntshav;Agonists ntawm Farnesoid X Receptor (FXR) raws li kev kho mob atherosclerosis;Butyrylcholinesterase inhibitors;Necroptosis inhibitors.